Suzhou Greenway

Suzhou Greenway Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, focused on the discovery and development of innovative small molecule drugs. The company primarily targets metabolic and renal diseases, with a significant emphasis on hyperuricemia and gout. Its lead candidate, GRW6211, is a potent and selective URAT1 inhibitor designed to lower serum uric acid levels by promoting excretion. Greenway was founded by industry veterans with extensive experience in global pharmaceutical R&D and operates within the Suzhou Biobay innovation hub. The company aims to address significant unmet medical needs in the chronic disease space through its internal medicinal chemistry and drug discovery capabilities. Currently, Greenway is advancing its lead programs through clinical trials in China while exploring further applications for its metabolic pipeline.